GSK3B and neoplasm: GSK-3β can recognize and phosphorylate β-catenin, generating a site that β-TrCP E3 Ub ligase can bind to, triggering the ubiquitination and degradation of β-catenin [36], thereby eliminating its EMT-promoting effect and reducing the metastasis of tumor cells.